S1931

Renal

Phase III Trial of Immunotherapy-Based Combination Therapy with or without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)

Key Team Members

Principal Investigator

Scott Graupner, DO

Research Coordinator

Taylor Knight

Accepting Patients

Enrollment Started: May 6, 2024

Check if You’re Eligible

(803) 935-8300

Research@lexhealth.org

About the Trial

The purpose of this study is to compare any good and bad effects of performing surgery to reduce the amount of cancer in the body. We wish to understand the effects of starting drug therapy followed by possible surgery and then more drug therapy.